Skip to main content

The SORT-IN-2 trial is a Phase 1b/2a proof-of-concept study evaluating the therapeutic potential of VES001, a novel oral treatment designed to target GRN mutations, which are the root cause of frontotemporal dementia.:

Source: Neurology Read More